Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AR and scents: a new way to soothe dementia symptoms?

NCT ID NCT07431164

Symptom relief Sponsor: National Taiwan Normal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether teaching older adults with early-stage dementia how to use aromatherapy through augmented reality (AR) can improve their mood and behavior. 300 participants in Taiwan will either receive AR-based aromatherapy education or standard activities. The goal is to see if this digital approach can reduce neuropsychiatric symptoms and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 65 years * AD-8 score ≥ 2, indicating suspected cognitive impairment * Ability to communicate and complete study questionnaires * No significant visual, hearing, or olfactory impairments * Willingness to participate in AR-based intervention sessions Exclusion Criteria: * Diagnosed psychiatric disorder * Complex chronic physical diseases * Moderate to severe dementia * Neuropsychiatric Inventory Questionnaire (NPI-Q) symptom score \> 3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia Health Education

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia Mild cognitive impairment (MCI) Neuropsychiatric symptoms

Contacts and locations

Locations

  • National Taiwan Normal University

    Taipei, Taipei City, 10610, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.